Author

L. J. Finney

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:human· 3 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:differential expression· 1 Assay:metagenomics· 1 Organism:mouse· 1

Frequent Co-Authors

A. Singanayagam· 3 shared M. Calderazzo· 3 shared P. Mallia· 3 shared S. L. Johnston· 3 shared J. Aniscenko· 2 shared J. Footitt· 2 shared M.-B. Trujillo-Torralbo· 2 shared N. W. Bartlett· 2 shared

Activity by Year

2019-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

A. Singanayagam

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon

L. J. Finney, N. Glanville, H. Farne, J. Aniscenko, P. Fenwick, S. Kemp, M.-B. Trujillo-Torralbo, M. Calderazzo, J. A. Wedzicha, P. Mallia, N. W. Bartlett, S. L. Johnston, A. Singanayagam

This study shows inhaled corticosteroids reduce ACE2 expression in COPD, potentially lowering SARS-CoV-2 susceptibility by suppressing type I interferon.

bioRxiv · Jun 13, 2020Immunology

MUC5AC drives COPD exacerbation severity through amplification of virus-induced airway inflammation

A. Singanayagam, J. Footitt, B. T. Kasdorf, M. Marczynski, M. T. Cross, L. J. Finney, M.-B. Trujillo Torralbo, M. Calderazzo, J. Zhu, J. Aniscenko, T. B. Clarke, P. L. Molyneaux, N. W. Bartlett, M. F. Moffatt, W. O. Cookson, , S. L. Johnston

This study identifies MUC5AC as a driver of COPD exacerbation severity by amplifying virus-induced airway inflammation through ATP release.

bioRxiv · Jul 22, 2019Immunology

Anti-microbial immunity is impaired in COPD patients with frequent exacerbations

A. Singanayagam, S.-L. Loo, M. Calderazzo, L. J. Finney, M.-B. Trujillo-Torralbo, E. Bakhsoliani, J. L. Girkin, P. C. Veerati, P. S. Pathinayake, K. S. Nichol, A. T. Reid, J. Footitt, S. L. Johnston, N. Bartlett, P. Mallia

This study identifies impaired anti-viral and anti-microbial immunity in COPD patients with frequent exacerbations, linking reduced interferon and MBL-2 levels to increased bacterial loads and susceptibility to exacerbations.

bioRxiv · May 9, 2019 · PreprintImmunology